Nanomedicine

Nanomedicine has been studied in 4 papers since 2022: none in people yet, 4 reviews; 2 in the past year. No study of it in people or animals has been published yet. The newest paper, May 5, 2026: “Translational nanomedicine strategies for selective senescent cell clearance in aging and age-related diseases: a critical review”.

4 papers study it3 findingsUpdated May 5, 2026

What did studies of Nanomedicine find?

Studies of Nanomedicine measured 3 outcomes; the most studied are senolytic index (1 study), apoptosis (1) and energy metabolism (1).

Senolytic index

upin reviews1

1 study

Nanomedicine improves senolytic index.
“Nanomedicine should therefore be viewed not as generic drug packaging, but as a strategy to improve the senolytic index through controlled exposure, multi-step selectivity, intracellular delivery, and context-responsive release.”
Review
Translational nanomedicine strategies for selective senescent cell clearance in aging and age-related diseases: a critical review
Therapeutic deliveryMay 5, 2026

Apoptosis

downin reviews1

1 study

Nanomedicine decreases apoptosis.
“These approaches show promise in restoring redox balance, improving energy metabolism, limiting apoptosis, and enhancing mitochondrial quality control”
Reviewin conditions such as ischemia-reperfusion injury, hypertension, heart failure, and arrhythmia
Nanomedicine guiding mitochondrial function in the treatment of cardiovascular diseases: Mechanisms, latest developments, and clinical translation
Ageing research reviewsApr 10, 2026